Core Points - OSE Immunotherapeutics held its Annual General Meeting, where shareholders representing approximately 56% of the share capital and over 62% of voting rights participated in key decisions for the company's future [1] - Dr. Markus Cappel was elected as the new Chairman of the Board of Directors, expressing enthusiasm for advancing the company's promising pipeline and novel medicines [3] - The company has a strong pipeline of innovative drug candidates and has achieved positive clinical trial results, positioning it as a significant player in the immunotherapy landscape [4] Board of Directors - The shareholders voted in favor of appointing new directors, including Dr. Markus Cappel and Alexis Peyroles [2] - The new Board of Directors held its first meeting post-election and confirmed its confidence in the employees' commitment to developing novel medicines [5] Dr. Markus Cappel's Background - Dr. Markus Cappel has over thirty years of experience in the biotechnology sector and is recognized for his entrepreneurial spirit and achievements [6] - As Chief Business Officer of ChemoCentryx, he led product development and negotiations that secured commercial rights and development control in the U.S. [7] - He played a key role in ChemoCentryx's acquisition by Amgen for $4 billion, which represented a 116% premium [8] Company Overview - OSE Immunotherapeutics is dedicated to developing first-in-class assets in immuno-oncology and immuno-inflammation, addressing unmet patient needs [11] - The company collaborates with leading academic institutions and biopharmaceutical companies to bring transformative medicines to market [11]

OSE Immunotherapeutics Reports its Cash Position as of June 30, 2025 Nantes, France, September 25, 2025, 6 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reports its cash position as of June 30, 2025. Due to the Company’s Annual General Meeting being rescheduled to September 30, 2025, and to allow shareholders to first approve 2024 financial statements, the full 2025 half-year interim financial results will be published on October 15, 2025. Update on AbbVie Partnership related to ABBV ...

Core Points - A shareholders' agreement has been executed by 61 founding, historical, employee, and executive shareholders of OSE Immunotherapeutics, representing approximately 20.1% of voting rights, concerning the vote on resolutions for the Board of Directors at the general meeting scheduled for September 30, 2025 [1][2]. Group 1: Shareholders' Agreement - The Shareholders' Group holds approximately 15.7% of the share capital and approximately 20.1% of the voting rights of the Company [2]. - The Shareholders' Group has committed to vote in favor of the Board of Directors' proposed resolutions regarding its own composition and against the resolutions proposed by minority shareholders [3]. Group 2: General Meeting Participation - Shareholders can participate in the General Meeting either in person, by mail, online via VOTACCESS, or by granting proxy to the Chairman or another person of their choice [4][8]. - For any proxy granted without naming a proxyholder, the Chairman will vote in favor of the Board's resolutions and against all other resolutions [4]. Group 3: Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation, partnering with leading academic institutions and biopharmaceutical companies [6].

Core Insights - OSE Immunotherapeutics is committed to value creation through innovative therapies in immuno-oncology and immuno-inflammation, supported by a strong portfolio and balanced governance [1][3][6] Strategic Focus - The company aims to achieve significant clinical milestones in 2026, 2027, and 2028 for its two flagship programs, leveraging differentiated assets with robust clinical data [2][3] - Development plans include Phase 2b for Lusvertikimab and Phase 3 for Tedopi®, with an emphasis on maintaining momentum and engaging strategic partners [3][5] Governance and Shareholder Dynamics - A minority shareholder group proposes a return to a previous model focused on a single asset, Tedopi®, which the company views as risky and lacking a clear strategy for Lusvertikimab [4][6][7] - The company emphasizes the importance of its current governance structure and the risks associated with a complete board overhaul proposed by minority shareholders [7][8][9] Financial and Operational Outlook - The company is focused on ensuring business continuity and financing for Tedopi®'s Phase 3 trial while continuing the development of Lusvertikimab [5][13] - The current trajectory is aligned with industry standards and aims to preserve and maximize shareholder value through a balanced pipeline of assets [6][13]

Company Overview - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) to meet unmet patient needs [3] - The company collaborates with leading academic institutions and biopharmaceutical companies to create transformative medicines for serious diseases [3] Recent Developments - OSE Immunotherapeutics has launched its inaugural Newsletter aimed at individual shareholders and investors, marking the 10th anniversary of its listing on Euronext Paris [2] - The Newsletter will provide updates on company developments, insights into team efforts, and deeper discussions on topics typically covered in press releases [2] Communication Strategy - The Newsletter will be published regularly in both French and English and will be accessible in the "Investors" section of the OSE Immunotherapeutics website [2] - This initiative is intended to enhance communication with individual shareholders and express appreciation for their continued support [2]

Core Points - OSE Immunotherapeutics has requested an extension for the Combined General Meeting scheduled for June 25, 2025, to ensure a regular and transparent process for shareholders [1][2][6] - The request is in response to shareholder concerns regarding the timely communication of resolutions aimed at changing the Board of Directors' composition [2][3] - The resolutions presented by a group of shareholders acting in concert have been renumbered from n°35 to 44 to A to K, with the content remaining unchanged [4] Company Information - OSE Immunotherapeutics is a biotech company focused on developing first-in-class assets in immuno-oncology and immuno-inflammation [8] - The company collaborates with leading academic institutions and biopharmaceutical companies to develop transformative medicines for serious diseases [8] - OSE Immunotherapeutics is based in Nantes and Paris and is listed on Euronext [8]